Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces lethal error catastrophe in SARS-CoV-2. How this drug-induced mechanism of action might impact the emergence of resistance mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Donovan-Banfield, I’ah, Penrice-Randal, Rebekah, Goldswain, Hannah, Rzeszutek, Aleksandra M., Pilgrim, Jack, Bullock, Katie, Saunders, Geoffrey, Northey, Josh, Dong, Xiaofeng, Ryan, Yan, Reynolds, Helen, Tetlow, Michelle, Walker, Lauren E., FitzGerald, Richard, Hale, Colin, Lyon, Rebecca, Woods, Christie, Ahmad, Shazaad, Hadjiyiannakis, Dennis, Periselneris, Jimstan, Knox, Emma, Middleton, Calley, Lavelle-Langham, Lara, Shaw, Victoria, Greenhalf, William, Edwards, Thomas, Lalloo, David G., Edwards, Christopher J., Darby, Alistair C., Carroll, Miles W., Griffiths, Gareth, Khoo, Saye H., Hiscox, Julian A., Fletcher, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701236/
https://www.ncbi.nlm.nih.gov/pubmed/36435798
http://dx.doi.org/10.1038/s41467-022-34839-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701236/
https://www.ncbi.nlm.nih.gov/pubmed/36435798
http://dx.doi.org/10.1038/s41467-022-34839-9

Ejemplares similares